Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Prime Medicine, Inc.
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Upcoming Investor Conferences
May 30, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
May 08, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
May 01, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
April 29, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
April 23, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Participate in Upcoming Investor Conferences
February 28, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 20, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Announces Pricing of Upsized Public Offering
February 14, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Announces Proposed Public Offering of Common Stock
February 14, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
January 25, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
January 05, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Upcoming Investor Conferences
November 08, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 03, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
October 27, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
October 24, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
October 17, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Upcoming Investor Conferences
September 19, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Upcoming Investor Conferences
August 31, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 07, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
June 22, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Investor Conferences in June
May 31, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present at Virtual Investor Conferences in May
May 17, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
May 17, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023
From
Prime Medicine, Inc.
Via
GlobeNewswire
Tickers
PRME
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.